Therapy Areas: Infectious Diseases
Regencell Bioscience Posts Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19 in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
19 May 2022 - - Hong Kong-based bioscience company Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) has posted results from an analysis of a total of 51 individuals enrolled in its additional Eva...
Humanetics Expands Long-Haul COVID-19 Trial
19 May 2022 - - US-based clinical-stage pharmaceutical company Humanetics Corp has added two additional clinical sites to its long-haul COVID-19 study, which is focused on patients who were treated fo...
PDS Biotechnology names senior vice president Business Development
19 May 2022 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease v...
Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines
18 May 2022 - - French biopharmaceutical company Osivax, which is developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, has entered a resear...
AstraZeneca and RQ Biotechnology sign licence agreement for monoclonal antibodies against COVID-19
17 May 2022 - British-Swedish pharmaceutical and biotechnology company AstraZeneca announced on Tuesday that it has entered into a licence agreement with UK-based RQ Biotechnology Ltd for a portfolio ...
Ionpath Receives Thermo Fisher Investment to Support Spatial Proteomics Innovation
12 May 2022 - - US-based laboratory instrument maker Thermo Fisher Scientific (NYSE: TMO) has made a strategic investment in US-based spatial proteomics specialist Ionpath, Inc, the company said.
Related Headlines

SQZ Biotechnologies to Make First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with Stemcell Technologies on Research-Use-Only System to Fuel Preclinical Research

Citius selects Biorasi to support expansion of Mino-Lok trial outside of US

Medicago Announces Publication of Covifenz Phase 3 COVID-19 Vaccine Study Results

Dr. Jiong Ma Named to LinKinVax Board Member

Risk Factors for Severe COVID-19 in Hospitalized Adults Differ by Age, Study Finds

Alercell commences Leukaemia Fusion Gene Screening and Genotyping Kit distribution

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine Using Proprietary B-Tech Vector Platform

US Patent Granted Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods

New Data for Shionogi's COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance

Takeda Presents New Exploratory Analysis Showing Patients Treated with Livtencity Had Reductions in Hospitalization Rates and Length of Hospital Stay

Gilead Sciences Inc presents several new studies at ECCMIC 2022 and confirms Veklury activity in treating COVID-19

New data suggests Shionogi's COVID-19 pill shows rapid clearance of virus

Quanterix Granted Breakthrough Device Designation from US FDA for NfL Test for Multiple Sclerosis

Osivax Phase 2a Trial Results Published for Influenza Vaccine Candidate OVX836

Ascletis reveals the 3CLpro inhibitor ASC11 is effective against COVID-19